201980Japan as number one 21American as number one 20 198020 19701980 1980 1990 2 Vol. 21 No. 111999
1990 1010 21 (1)(2) (3) (4) Vol. 21 No. 111999 3
SSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSS 1999 10 4 Vol. 21 No. 111999
Vol. 21 No. 111999 5
32 24 20 8 7 b(hp) 23.78 14.95 12.05 5.36 5.01 50 g/m 3 16.9 10.9 8.9 4.1 3.8 0 35 35 3540 40 mb(hp) 9.51 5.97 4.82 2.47 2.30 20 g/m 3 6.8 4.4 3.6 1.9 1.8 17 36 63 66 40 30 70 3040 1997 18 1961 Harper g/m m 23 17 10g/m g/m 6 Vol. 21 No. 111999
1510g/m // 1510g/m 10g/m * / 3 4060 10/ 3 15 5 / 3 10 20 710 Vol. 21 No. 111999 7
17 g/m 12 30 451102097.3 g/m 3 461016 5.7 471723 5.2 482430 5.0 49120107 4.4 1148 5.0 g/m 3 111945 27 1 2911 19 3065 14 12 2 3 1 (H3N2) 30 10 4 8 Vol. 21 No. 111999
. 10 MDCK CPE -RNA EIA Directigen Flu A R Becton DickinsonUSA. HI test CF test 11 15 1980 1994 1998 99 1997 98759899150 150300 Vol. 21 No. 111999 9
7080 1,2,3 Howells CH, et allancet i381-383,1975 Patriaca PA, et aljama 2531136-1139,1985 Gross PA, et alarch Intern Med 148562-565,1988 Govaert ME,et al,jama 272:1661-1665,1994 92737 91182 p0.001 60/ 55:2751,'97 5 /9223/213p<0.1 72:60,'98 4 /86 12/123p<0.1 120:1009,'98 4 /16 49/84p<0.05 1994 R 20 11 7090 48 100200mg/ -167o64-0796 OTC,, BMY-27709 PM-523 RNA RNAPB GG-167 Ro64-0796GS4104 10 Vol. 21 No. 111999
608408481986 1998 30284428491981 1999 Harper,G.J.Airborne micro-organisms survival tests with four viruses. J.Hyg. Camb. 594794861961 47179718051995 Therapeutic Research 1912131217 1998 Vol. 21 No. 111999 11
13 Vol. 21 No. 111999 TG VLDL LDLHDL TG LPL TG VLDL VLDLTG IDLIDL TG TGHTGL TG LDLLDL LDL LDL HDLHDL VLDL HDL LDL
14 Vol. 21 No. 111999 500LDL LDL- LDL-C 100 LDL LDL-C 10 40 TG 300mg/dl 100 LDL TG HDL- HDL-C LDL-C VLDL C- HDL- SLE
15 Vol. 21 No. 111999 TG HDL-C TG TG HDL-C LPL VLDL TG HDL-C TG TG TG HDL-C TG HDL-CTG LPL HDL-C TG VLDLTG HDL-C LDL-C LDL-CHDL-C LDL-CHDL-C TG TG TG LDL LDL LDL LDL LDL
16 Vol. 21 No. 111999 LDL HDL TG TGHDL VLDLTG HDLTG HDL LDL LDL VLDLTG IDL TG silent disease 75 X TG1,000mg/dl mm 200mg/dl LDL-C140mg/dl TG150mg/dl TGHDL-C40mg/dl HDL-C LDL-C 200mg/dl120mg/dl 200219mg/dl120139mg/dl TGHDL-C 12 WHO ab
a b VLDL -VLDL or LDL VLDL LDL IDL VLDL TC TC TC TC TCor TC TG TG TG TG TG TG 6015 202025 25g E C- 20 300mg SM P1.5 200mg SMP0.71.5 253050 601520 25g 300mg 25g 40g P/S1.02.0W-3 W-3 TGVLDL 200mg 5025g 40g 40 P/S New York Anticoronary Club Study, Finnish Mental Hospital Study, Los Angeles Veterans Administration Study LDL-C TGHDL- C Vol. 21 No. 111999 17
1,200mg 1,5002,250mg - 300mg A 600mg EPL 1,500mg 120180mg MDS 1,800mg 0.751.5mg 23g 6001,200mg 7501,500mg B 7501,500mg 7501,500mg 1,500mg 600mg 400mg 300mg * CI-719 900mg EPA 1,8002,700mg 812g1827g 3g 5001,000mg HMG-CoA C 1020mg 510mg 2060mg 150300mg * CI-981 50 138 15 10138 30 180 18 Vol. 21 No. 111999
19 Vol. 21 No. 111999 A BTG TG C Evidence based medicine HMG-CoA mg HMG-CoA EPATG
EPA 1,800mg EPA 100mg 200mg EPA Lipid Research Clinics Coronary Primary Prevention TrialLRC-CPPT Helsinki Heart StudyHHS West of Scotland Coronary Prevention StudyWOSCOPSAir Force/Texas Coronary Atherosclerosis Prevention StudyAFCAPS/Tex CAPS Pravastatin Multinational Study PMNSCholesterol and Recurrent Events CARELong-Term Intervention with Pravastatin in Ischaemic DiseaseLIPID Scandinavian Simvastatin Survival Study4S 20 Vol. 21 No. 111999
21 Vol. 21 No. 111999 25 25 25 AA 25 kg 1000mg 250mg mg 10mg mg 10mg 10mg mg mg mg mg 1.3mg mg mg mg 50mg 340mg 20100 mg
22 Vol. 21 No. 111999 kg1000mg 1000mg25 ph8.5 U
23 Vol. 21 No. 111999
24 Vol. 21 No. 111999 1232349 4430 25 600 80 100 47 41
0428(74)4221 0428(74)5305 0428(74)5655 0428(85)2221 0428(83)2027 0428(86)2155 0428(86)2026 0428(86)2136 0428(86)2247 0428(86)2066 0428(86)2222 0428(86)2207 0428(86)2151 0428(86)2217 0428(86)2245 0428(86)2533 0428(86)2235 0428(86)2132 0428(86)2253 0428(86)2017 0428(85)2340 0428(85)2231 0428(85)2223 0428(85)2158 0428(83)2363 0428(83)2122 0428(83)2170 0428(83)3461 0428(83)2365 0428(83)2112 042(598)6001 042(598)6789 042(598)6789 042(597)1126 0426(77)8787 0426(76)8848 0425(91)0820 0425(91)0820 042(734)4847 042(734)4847 042(796)0426 042(774)2681 03(3401)8324 03(3404)2610 2002 03(3376)4423 03(3844)4141 03(3781)0265 Vol. 21 No. 111999 25
03(3781)0575 03(3471)8949 03(3491)4856 03(3712)0356 03(3713)1005 03(3751)0119 03(3768)9121 03(3758)2845 03(3751)3003 03(3729)4526 03(3731)0024 03(3753)5845 03(3753)0455 03(3734)6561 03(3753)6901 03(3732)1126 03(3731)1993 03(3739)5527 Na,Ca,Mg 03(3742)7846 03(3731)5342 03(5711)1126 NU-LAND 03(3739)1126 03(3744)1822 HM 03(3730)2665 Na 03(3700)1320 21 03(3483)2611 03(3413)6328 03(3702)3305 03(3707)8221 03(3467)2502 03(3339)9224 03(3623)1695 03(3631)4126 03(3644)6089 03(3689)0676 03(3680)5611 04992(2)1673 04992(2)1441 04992(2)2551 04992(2)3581 04992(2)1313 04992(2)1149 04992(2)2571 04992(2)1550 04992(5)0830 04992(5)0240 04992(5)0240 04992(5)0240 04992(5)0240 04992(8)0131 26 Vol. 21 No. 111999
04992(8)1376 04994(5)0519 04994(5)0426 04996(8)0211 04996(8)0345 04996(2)1121 04996(2)1121 04996(2)1121 04996(2)1121 BOOM 04996(2)1121 04996(2)1121 Vol. 21 No. 111999 27
28 Vol. 21 No. 111999 189730 200 6581987 198863100 1996 PR AA 19601970
1983 2001984 1997658 ph B2202-(1) 201204 Vol. 21 No. 111999 29
30 Vol. 21 No. 111999
31 Vol. 21 No. 111999 4043 3639 3941 cm cm 1/960kg 6.26.3kg
60-1051935 6368-3731982 5216-181988 47130-1361984 541-121984 4989-941986 Percutaneous Absorption of 14 CO2 during 14 CO2-Bathing in Rabbits 55207-2141992 44128-1371981 6432-351984 10 6922-261984 11 7721-251986 12 21 219-2221987 13 6955-581984 14 58115-1201995 15 5297-1031989 16B1 44646-6491991 17 16119-1241992 18 30-351993 40 4243 3638 4243 40 4243 3941 32 Vol. 21 No. 111999
JR40 50 201945 40 25 788 14823 34 Vol. 21 No. 111999
35 Vol. 21 No. 111999 1625 7941192 767 15961615 1616 1617 1655 cm200 cm400 371962 800 m 2.5m 11 11
198-0211 760 0428-83-20998352 1955 stalactite stalactitestalagmite calcium carbonate, CaCO3calcite cm 0.5cm marblelime stone aragonite chalk 36 Vol. 21 No. 111999
CaCl2 NaCO3 precipitated calcium carbonate 1987 1914 1712 1993 Balanophyllia sp. Stalactite 15g Vol. 21 No. 111999 37
1520g 6033 38 Vol. 21 No. 111999
ddddddddddddddddddddddddddddddddddddddddddddd ddddddddddddddddddddddddddddddddddddddddddddd Vol. 21 No. 111999 41
42 Vol. 21 No. 111999
C1 C3b C3aC5a C9 Vol. 21 No. 111999 43
44 Vol. 21 No. 111999
Vol. 21 No. 111999 45
BCG2472 46 Vol. 21 No. 111999
Fc Vol. 21 No. 111999 47
994 995 10 14 30 9661027 10161017 1018101653 10 48 Vol. 21 No. 111999
53 30 10 102762 10 1110 1129 30 12 12 Vol. 21 No. 111999 49
51 Vol. 21 No. 111999 10 10 10 1050 50 500 791126 30 130 10 10 10
101131 406,813,000 406,621,000 359,067,250 334,622,095 104,348,000 105,846,882 151,290,000 149,971,044 18,859,400 18,859,000 16,800,000 13,177,173 27,406,000 27,406,000 84,384,000 84,384,000 6,000 1,100,000 20,440,000 20,377,671 2,900,000 4,402,657 2,000 0 75,015,118 75,488,074 3,364,268 0 A 635,347,518 639,723,613 B 635,347,518 602,531,983 CAB 0 37,191,630 8,415,000 6,514,349 4,900,000 3,343,861 12,450,000 10,056,200 700,000 2,803,379 1,350,000 1,511,802 7,510,000 7,554,054 10,750,000 8,246,017 2,700,000 3,733,386 1,800,000 1,729,901 10 749,000 737,380 11 29,996,000 28,329,493 12 6,700,000 6,661,305 13 18,652,000 18,745,540 14 3,530,000 1,874,987 15 500,000 496,944 16 500,000 172,367 17 1,000,000 1,000,000 18 53,870,250 53,353,200 19 4,000,000 2,919,093 20 4,000,000 1,584,810 21 4,000,000 3,699,097 22 2,200,000 1,857,346 2350 15,000,000 9,559,983 24 350,000 350,000 25 200,000 198,310 26 463,000 459,000 27 27,896,000 28,541,485 28 134,886,000 128,588,806 35 9,300 6,570 PEM H2 12 869 52 Vol. 21 No. 111999
53 Vol. 21 No. 111999 78 28 103.3 30
54 Vol. 21 No. 111999 300 10 20 20 212B 16.7 392A 2A2B 7063 1A1B2070 2A 23 40 GE 30 23 74
55 Vol. 21 No. 111999 12 700 20 74 70074 10 10 OTC 700 10 OTC 700
56 Vol. 21 No. 111999 21 OTC 62 2122 10 12 10
57 Vol. 21 No. 111999 NHK 99 20 22 20 10241700 50 37 142 731 381
58 Vol. 21 No. 111999
59 Vol. 21 No. 111999 4,3134,267 10 10 23 38 11 1800 23 55
6-7-1 192-0355 1703-3-3 10426-76-6706 FAX0426-75-8964 5,000 SST H65-9-1 TEL042-748-9111 FAX042-746-8906 3,000 RAD-AR TEL. 3663-8891 34 1012-522-1 5830 60 Vol. 21 No. 111999 103-3817-5821 FAX03-3817- 21 OTC 26 103-3357-5333 FAX03-3357-5776 E-mailnichibei@cd.mbn.or.jp 8,000 5,0002,000 00110-6- 413507 426402 TDM TDMTDM 5-9-1 TEL03-3444-6191 FAX03-3442-5674 5,000 15,000 1130FAX
63 Vol. 21 No. 111999 5011 2627 10 80 20 11 13 16 17 18 20 21 22 24
64 Vol. 21 No. 111999 21 11 121231 PRNHK 9/2110/1911/16 92 1031 12 10 1296 11 12 0801-70025890 13 1412 1515 1622 17 99 18 11 14 16 17 18 24 25 29 30
65 Vol. 21 No. 111999 197,904 110 in TOKYO 110 16 30 10 11 363165 259 HIV 10 10 2010 31.09.006.107-79-2 07-450-3 10 101130 1111 12 13 14 15 1650 17 18 12 11 6,521 114,160 500 113,120 500
11112226 2000 2000 2,000 2013-9-10 112111386 300 101-0054 1 21 132940271 66 Vol. 21 No. 111999